Abstract
REM (rapid eye movement) sleep behavior disorder (RBD) is a well known parasomnia [1]. Its first description in humans dates back to 1985, and its first description in narcoleptic patients to 1992. Although the precise pathophysiology of RBD remains unclear, it is likely, in the case of RBD associated with narcolepsy, that the altered function of hypocretin pathways projecting from the lateral hypothalamus to the ventrolateral part of the periaqueductal grey matter and the lateral pontine tegmentum has a consistent role. The percentage of narcoleptic patients complaining of clinical RBD lies somewhere between 10 and 15% of the narcoleptic population. The age of onset is younger than in the other forms of chronic RBD. Clinical features are the same as in the other forms of chronic RBD, but the frequency of the episodes is less marked. Associated features include other parasomnias, periodic limb movements in sleep (PLMs) and olfactory dysfunction. Polysomnographic tracings are remarkable for elevated submental electromyographic (EMG) tone and/or excessive phasic submental EMG twitching. Data on human leukocyte antigen (HLA) association and on cerebrospinal fluid (CSF) hypocretin/orexin levels are limited. Clinical variants include RBD induced or worsened by pharmacological agents, most of them being used to treat cataplexy, RBD in narcoleptic children and RBD in the context of symptomatic narcolepsy. Several treatments of RBD are available including clonazepam, melatonin and more recently pramipexole. However, in the absence of any pharmacological trials of these drugs on RBD in narcoleptic patients, it is difficult to provide guidance other than to recommend conventional treatments of RBD.
Keywords: Narcolepsy, REM sleep behavior disorder, Pathophysiology, Epidemiology, Clinical variants, Hypocretin/orexin
CNS & Neurological Disorders - Drug Targets
Title: REM Sleep Behavior Disorder and Narcolepsy
Volume: 8 Issue: 4
Author(s): Michel Billiard
Affiliation:
Keywords: Narcolepsy, REM sleep behavior disorder, Pathophysiology, Epidemiology, Clinical variants, Hypocretin/orexin
Abstract: REM (rapid eye movement) sleep behavior disorder (RBD) is a well known parasomnia [1]. Its first description in humans dates back to 1985, and its first description in narcoleptic patients to 1992. Although the precise pathophysiology of RBD remains unclear, it is likely, in the case of RBD associated with narcolepsy, that the altered function of hypocretin pathways projecting from the lateral hypothalamus to the ventrolateral part of the periaqueductal grey matter and the lateral pontine tegmentum has a consistent role. The percentage of narcoleptic patients complaining of clinical RBD lies somewhere between 10 and 15% of the narcoleptic population. The age of onset is younger than in the other forms of chronic RBD. Clinical features are the same as in the other forms of chronic RBD, but the frequency of the episodes is less marked. Associated features include other parasomnias, periodic limb movements in sleep (PLMs) and olfactory dysfunction. Polysomnographic tracings are remarkable for elevated submental electromyographic (EMG) tone and/or excessive phasic submental EMG twitching. Data on human leukocyte antigen (HLA) association and on cerebrospinal fluid (CSF) hypocretin/orexin levels are limited. Clinical variants include RBD induced or worsened by pharmacological agents, most of them being used to treat cataplexy, RBD in narcoleptic children and RBD in the context of symptomatic narcolepsy. Several treatments of RBD are available including clonazepam, melatonin and more recently pramipexole. However, in the absence of any pharmacological trials of these drugs on RBD in narcoleptic patients, it is difficult to provide guidance other than to recommend conventional treatments of RBD.
Export Options
About this article
Cite this article as:
Billiard Michel, REM Sleep Behavior Disorder and Narcolepsy, CNS & Neurological Disorders - Drug Targets 2009; 8 (4) . https://dx.doi.org/10.2174/187152709788921690
DOI https://dx.doi.org/10.2174/187152709788921690 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in the Development of Inactivated Virus Vaccines
Recent Patents on Anti-Infective Drug Discovery Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies
Current Alzheimer Research Measles Virus Induced Immunosuppression: Targets and Effector Mechanisms
Current Molecular Medicine Optimization on Fc for Improvement of Stability and Aggregation Resistance
Current Pharmaceutical Biotechnology Inhibition of West Nile virus Replication by Bifunctional siRNA Targeting the NS2A and NS5 Conserved Region
Current Gene Therapy Editorial [Hot Topic: The Challenge of Viral Encephalitis: From Etiological Diagnosis to Efficient Antiviral Drug Discovery (Guest Editor: Laurent Dacheux)]
Infectious Disorders - Drug Targets Demographic, Clinical and Laboratory Profiles of HIV Infected Patients Admitted into Imam Khomeini Hospital of Tehran, Iran
Infectious Disorders - Drug Targets The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine Pathways by Which Aβ Facilitates Tau Pathology
Current Alzheimer Research Dengue Fever: Theories of Immunopathogenesis and Challenges for Vaccination
Inflammation & Allergy - Drug Targets (Discontinued) A Systems Biology Perspective on Rational Design of Peptide Vaccine Against Virus Infections
Current Topics in Medicinal Chemistry Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism,Carbohydrate Metabolism, and Innate Immunity
Current Signal Transduction Therapy Molecular Mechanism of Aniline Induced Spleen Toxicity and Neuron Toxicity in Experimental Rat Exposure: A Review
Current Neuropharmacology A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
CNS & Neurological Disorders - Drug Targets ABC Transporters in the CNS – An Inventory
Current Pharmaceutical Biotechnology Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) West Nile Virus NS2B/NS3 Protease As An Antiviral Target
Current Medicinal Chemistry Superheated Water as Solvent in Microwave Assisted Organic Synthesis of Compounds of Valuable Pharmaceutical Interest
Current Organic Chemistry